. | Incidence of type 2 diabetes . | Incidence of IFG/type 2 diabetes . | Incidence of metabolic syndrome . | |||
---|---|---|---|---|---|---|
HR (95% CI) . | P . | HR (95% CI) . | P . | OR (95% CI) . | P . | |
T3 vs. T1 | 0.38 (0.26–0.55) | <0.0001 | 0.73 (0.58–0.92) | 0.007 | 0.72 (0.56–0.92) | 0.009 |
T2 vs. T1 | 0.78 (0.57–1.07) | 0.12 | 0.99 (0.80–1.23) | 0.97 | 0.93 (0.73–1.19) | 0.58 |
T3 vs. T2 | 0.49 (0.32–0.72) | 0.0003 | 0.73 (0.59–0.93) | 0.008 | 0.77 (0.60–0.98) | 0.04 |
log(apelin) | 0.79 (0.70–0.89) | 0.0002 | 0.91 (0.83–0.98) | 0.04 | 0.91 (0.83–1.01) | 0.09 |
. | Incidence of type 2 diabetes . | Incidence of IFG/type 2 diabetes . | Incidence of metabolic syndrome . | |||
---|---|---|---|---|---|---|
HR (95% CI) . | P . | HR (95% CI) . | P . | OR (95% CI) . | P . | |
T3 vs. T1 | 0.38 (0.26–0.55) | <0.0001 | 0.73 (0.58–0.92) | 0.007 | 0.72 (0.56–0.92) | 0.009 |
T2 vs. T1 | 0.78 (0.57–1.07) | 0.12 | 0.99 (0.80–1.23) | 0.97 | 0.93 (0.73–1.19) | 0.58 |
T3 vs. T2 | 0.49 (0.32–0.72) | 0.0003 | 0.73 (0.59–0.93) | 0.008 | 0.77 (0.60–0.98) | 0.04 |
log(apelin) | 0.79 (0.70–0.89) | 0.0002 | 0.91 (0.83–0.98) | 0.04 | 0.91 (0.83–1.01) | 0.09 |
Hazard ratio (HR) or odds ratio (OR) with 95% CI computed by Cox proportional hazards survival regression analysis or logistic regression analysis, respectively, and adjusted for sex and age. Data expressed for tertiles (T) of plasma apelin, and for 1 SD of log(apelin). P < 0.05 is significant.